Idarucizumab to reverse effects of anticoagulant dabigatran

    loading  Checking for direct PDF access through Ovid

Abstract

Idarucizumab (Praxbind) is a new treatment to reverse the effects of the nonvitamin K antagonist oral anticoagulant (NOAC) dabigatran if emergency surgery is needed or to prevent life-threatening or uncontrolled bleeding. This article describes its properties, efficacy and adverse effects.

Related Topics

    loading  Loading Related Articles